Derieux S, Svrcek M, Manela S, et al. - Through the use of Mandard's Tumor Regression Grade (TRG) in gastric cancer, researchers evaluated the prognostic ability of pathological response to chemotherapy and identified predictive factors for the response to chemotherapy. Patients with gastric adenocarcinoma were retrospectively identified from two institutional surgical databases who had preoperative chemotherapy and subsequent gastrectomy. One hundred nine underwent preoperative chemotherapy out of 325 patients resected from a gastric cancer between 1997 and 2016. Data reported that 42% were pathologic responders (TRG1-3) and 58% non-responders (TRG4-5). Five-year overall survival (OS) was 35% for non-responders and 73% for responders. In patients resected for gastric adenocarcinoma, TRG after preoperative chemotherapy is an important prognostic factor. In order to assess whether adjuvant therapy should be tailored to the pathological response, further research should be conducted.